Profile data is unavailable for this security.
About the company
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
- Revenue in USD (TTM)0.00
- Net income in USD-2.54m
- Incorporated2021
- Employees8.00
- LocationCERo Therapeutics Holdings Inc201 Haskins Way, Suite 230SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (215) 731-9450
- Fax+1 (302) 636-5454
- Websitehttps://www.phoenixbiotechacquisitioncorp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Windtree Therapeutics Inc | 0.00 | -5.96m | 4.91m | 15.00 | 0.4475 | 0.2743 | -- | -- | 18.53 | 18.53 | 0.00 | 30.23 | 0.00 | -- | -- | 0.00 | -18.26 | -44.51 | -20.72 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -400.47k | 4.98m | 0.00 | -- | 12.54 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0011 | 0.00 | -- | -- | -- | -88.14 | -696.88 | -101.62 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Biostax Corp | 0.00 | -1.57m | 5.01m | -- | -- | -- | -- | -- | -0.0188 | -0.0188 | 0.00 | -0.058 | 0.00 | -- | -- | -- | -390.77 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -6.05 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -17.06m | 5.10m | 10.00 | -- | 0.3745 | -- | -- | -206.36 | -206.36 | 0.00 | 0.7893 | 0.00 | -- | -- | 0.00 | -264.82 | -133.14 | -721.90 | -181.26 | -- | -- | -- | -- | -- | -148.05 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Ainos Inc | 93.68k | -14.56m | 5.19m | 46.00 | -- | 0.1835 | -- | 55.40 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.69m | 5.22m | 3.00 | -- | -- | -- | -- | -2.38 | -2.38 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -118.45 | -104.18 | -130.17 | -111.05 | -- | -- | -- | -- | -- | -1,253.20 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -12.23m | 5.24m | 5.00 | -- | 0.2091 | -- | -- | -37.38 | -37.38 | 0.00 | 21.08 | 0.00 | -- | -- | 0.00 | -13.75 | -40.33 | -15.54 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.10m | 5.27m | 8.00 | -- | 0.265 | -- | -- | -14.03 | -14.17 | 0.00 | 19.06 | 0.00 | -- | -- | 0.00 | -49.97 | -- | -53.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Helix BioMedix, Inc. | 2.07m | -2.58m | 5.28m | 8.00 | -- | 3.38 | -- | 2.56 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 5.29m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| BioCardia Inc | 468.00k | -10.34m | 5.44m | 16.00 | -- | -- | -- | 11.63 | -7.04 | -7.04 | 0.3132 | -1.27 | 0.0954 | -- | 4.44 | 29,250.00 | -210.81 | -107.34 | -1,190.90 | -154.17 | -- | -- | -2,208.76 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Burzynski Research Institute Inc | 0.00 | -1.42m | 5.52m | 2.00 | -- | -- | -- | -- | -0.0108 | -0.0108 | 0.00 | -0.001 | 0.00 | -- | -- | -- | -153,444.30 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -9.89m | 5.61m | 21.00 | -- | 0.2358 | -- | -- | -1.26 | -1.26 | 0.00 | 0.3388 | 0.00 | -- | -- | 0.00 | -168.89 | -132.00 | -228.29 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| Notable Labs Ltd | 311.00k | -12.39m | 5.64m | 16.00 | -- | 0.4882 | -- | 18.12 | -2.31 | -2.31 | 0.0622 | 1.28 | 0.0142 | -- | -- | 19,437.50 | -56.70 | -52.02 | -74.10 | -62.09 | 37.30 | 60.19 | -3,984.24 | -3,636.93 | -- | -- | 0.0271 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
Data as of Jul 29 2024. Currency figures normalised to CERo Therapeutics Holdings Inc's reporting currency: US Dollar USD
0.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Jane Street Capital LLCas of 31 Mar 2024 | 26.52k | 0.18% |
| Birchview Capital LPas of 31 Mar 2024 | 12.97k | 0.09% |
| Geode Capital Management LLCas of 31 Mar 2024 | 10.59k | 0.07% |
| FNY Capital Management LPas of 31 Mar 2024 | 10.50k | 0.07% |
| Kestra Private Wealth Services LLCas of 31 Mar 2024 | 10.00k | 0.07% |
| Pineridge Advisors LLCas of 30 Jun 2024 | 300.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 2.00 | 0.00% |
| Clear Street LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| W.R. Berkley Corp. (Investment Portfolio)as of 31 Mar 2024 | 0.00 | 0.00% |
| Mint Tower Capital BVas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
